The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).
Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.
Alzheimer's Association recently released recommendations about using blood-based biomarkers to detect Alzheimer’s disease. The recommendations are based on research conducted by Oskar Hansson, one of MultiPark’s research group leaders.
“Blood-based biomarkers for Alzheimer’s are already improving the design of clinical trials, and they are very likely to revolutionize the diagnosis of Alzheimer’s in the future,” says Oskar Hansson in Alzheimer’s associations press release.
Read the full press release here.
The scientific article “The Alzheimer's Association Appropriate Use Recommendations for Blood Biomarkers in Alzheimer’s Disease,” by Oskar Hansson, M.D., Ph.D., et al, was published 31 July 2022 by Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Oskar Hansson
Professor and senior consultant in neurology
oskar [dot] hansson [at] med [dot] lu [dot] se (oskar[dot]hansson[at]med[dot]lu[dot]se)
0722-26 77 45
Oskar Hanssons profile in Lund University research portal
Twitter: @oskarhansson9
Homepage: https://biofinder.se
